Critical Care volume 15, Article number: P35 (2011)
AB103 is a novel CD28 antagonist peptide currently in clinical development that modulates CD28 signaling in T cells, without affecting the normal humoral immune response. In experimental models of Gram-positive, Gram-negative and polymicrobial sepsis, AB103 demonstrated significant activity, increasing overall survival.
The AB103 activity and mode of action (MOA) were evaluated in a murine model of cecal ligation and puncture (CLP). AB103 (5 mg/kg) was administered to mice (Balb/c) at various times points following CLP (2 to 24 hours), together with moxifloxacin.
A single dose of AB103, given at 12 or 24 hours post CLP, rescued 100% and 62.2% of the animals (respectively) from sepsis-induced mortality, whereas moxifloxacin alone (LD90, given at 12 hours) rescued only 25% (P < 0.05) of the animals. In a separate set of experiments investigating the MOA, AB103 administration (5 mg/kg, given without antibiotics 2 hours post CLP) was associated with: a reduction in Th-1 cytokine levels in peritoneum (TNFα, IL-3, IL-17 and Rantes) and plasma (IL-3 and IL-6); a reduction in splenocyte proliferation, stimulated ex vivo with anti-CD3 and anti-CD28 antibodies; a reduction in neutrophil recruitment to the spleen, liver and kidney, as determined by MPO activity; and a reduced bacterial load in peritoneum, blood and tissues (kidney, liver, spleen).
These data demonstrate that attenuation of CD28 signaling is a viable therapeutic approach to the treatment of sepsis. Due to its robust activity and good safety profile in humans already established in a phase 1 study, AB103 should be clinically evaluated in sepsis patients.
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Teleman, D., Chung, CS., Ayala, A. et al. AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis. Crit Care 15 (Suppl 3), P35 (2011). https://doi.org/10.1186/cc10404
Published:
DOI: https://doi.org/10.1186/cc10404
Critical Care